Abstract | OBJECTIVE: STUDY DESIGN: In a randomized, placebo-controlled, double-blind study, healthy hysterectomized postmenopausal women received daily either placebo (n=49), transdermal 17beta-estradiol (E(2)) 50 microg (tE(2) group, n=33), oral E(2) 1 mg (oE(2) group, n=37), or oral E(2) 1 mg combined with gestodene 25 microg (oE(2)+G group, n=33) for thirteen 28-day treatment cycles. Hemostatic variables were measured in blood samples collected at baseline and in cycles 4 and 13. RESULTS: No significant changes versus baseline and placebo were found in the tE(2) group, except for plasminogen activator inhibitor type-1 (PAI-1) in cycle 13 (-32.4%, P=.01). In the oE(2) group, significant percentage changes from baseline versus placebo in cycle 13 were found in fibrinogen, -5.4% (P<.05); factor VII, -7.3% (P<.05); thrombin- antithrombin III complexes, -13.3% (P<.05); tissue-type plasminogen activator (t-PA), -17.3% (P<.001); and PAI-1, -54.3% (P<.001). In the oE(2)+G group, respective changes were factor VII, -17.6% (P<.001); t-PA, -14.5% (P=.01); PAI-1, -36.4% (P<.01); and D-dimer, +21.8% (P<.05). No significant changes were observed in prothrombin fragment 1+2 and plasmin-alpha(2)-antiplasmin complexes. CONCLUSION: Low-dose oral estradiol therapy was associated with an increase in fibrinolysis and small decreases in procoagulant variables. Transdermal therapy had minor effects.
|
Authors | Marinka S Post, Marius J van der Mooren, W Marchien van Baal, Marinus A Blankenstein, Hans M W M Merkus, Maurice V A M Kroeks, Henk R Franke, Peter Kenemans, Coen D A Stehouwer |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 189
Issue 5
Pg. 1221-7
(Nov 2003)
ISSN: 0002-9378 [Print] United States |
PMID | 14634544
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Administration, Cutaneous
- Administration, Oral
- Blood Coagulation
(drug effects)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Estradiol
(administration & dosage)
- Estrogen Replacement Therapy
- Female
- Fibrinolysis
(drug effects)
- Hemostasis
(drug effects)
- Humans
- Middle Aged
- Postmenopause
(blood)
- Reference Values
|